SIGA Technologies Inc. (SIGA)
NASDAQ: SIGA
· Real-Time Price · USD
5.61
0.18 (3.31%)
At close: May 02, 2025, 3:04 PM
Company Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States.
Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.
The company was incorporated in 1995 and is headquartered in New York, New York.
SIGA Technologies Inc.
| Country | United States |
| IPO Date | Sep 10, 1997 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Dr. Diem Nguyen M.B.A., Ph.D. |
Contact Details
Address: 31 East 62nd Street New York, New York United States | |
| Website | https://www.siga.com |
Stock Details
| Ticker Symbol | SIGA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001010086 |
| CUSIP Number | 826917106 |
| ISIN Number | US8269171067 |
| Employer ID | 13-3864870 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Diem Nguyen M.B.A., Ph.D. | Chief Executive Officer & Director |
| Herb Vloedman | Senior Vice President & Chief Information Officer |
| Dr. Dennis E. Hruby Ph.D. | Executive Vice President & Chief Scientific Officer |
| Tove C. Bolken | Senior Vice President of Operations & Chief Supply Chain Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Filing |
| Apr 28, 2025 | DEF 14A | Filing |
| Apr 25, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 21, 2025 | 4 | Filing |
| Apr 18, 2025 | PRE 14A | Filing |
| Apr 08, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 4 | Filing |
| Mar 19, 2025 | 4 | Filing |
| Mar 19, 2025 | 3 | Filing |